Patent intelligence · US
US 12208099
Combination therapies
Combination therapies
Patent details — US 12208099
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 28, 2025
- Expiration
- Jan 23, 2045
- Applicant
- Mirati Therapeutics, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K31/428, A61K31/4375, A61K31/44
Quick answer
US 12208099 (Combination therapies) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/428, A61K31/4375, A61K31/44, A61K31/4985, A61K31/506
More from Mirati Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 12208099?
US 12208099 (Combination therapies) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12208099?
Mirati Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 12208099 expire?
Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.